SG Americas Securities’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

SG Americas Securities’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8	Closed	-$5K	–	3511
2023 Q3	$5K	Sell	8 -1	-11%	-$4.29K	﹤0.01%	3073
2023 Q2	$40K	Sell	9 -1	-10%	-$3.47K	﹤0.01%	2146
2023 Q1	$26K	Sell	10 -2	-17%	-$5.86K	﹤0.01%	3135
2022 Q4	$31K	Sell	12 -2	-14%	-$6.97K	﹤0.01%	2893
2022 Q3	$56K	Buy	+14	New	+$55.1K	﹤0.01%	2979
2022 Q1	–	Sell	-3	Closed	-$20K	–	3551
2021 Q4	$20K	Sell	3 -6	-67%	-$46.1K	﹤0.01%	3268
2021 Q3	$81K	Buy	9 +4	+80%	+$34.4K	﹤0.01%	3696
2021 Q2	$52K	Buy	+5	New	+$82.2K	﹤0.01%	2735

Other funds holding SEEL

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SG Americas Securities's SEEL Position: Q4 2023 in Review

SG Americas Securities sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 8 shares — an estimated $5K sold.

SG Americas Securities first reported a position in SEEL in Q2 2021 and held it in 8 quarters. The position peaked at $81K in Q3 2021. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

SG Americas Securities reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
SG Americas Securities sold 8 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $5K.
SG Americas Securities first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
SG Americas Securities's Seelos Therapeutics, Inc. Common Stock position peaked at $81K in Q3 2021.
32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on SG Americas Securities's 13F filing for Q4 2023, filed 12 Jan 2024.